Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX plus lenvatinib, iparomlimab, and tuvonralimab for first-line unresectable or metastatic intrahepatic cholangiocarcinoma
ChiCTR2600132618Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, oxaliplatin, lenvatinib, iparomlimab and tuvonralimab in intrahepatic cholangiocarcinoma (ICC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
gemcitabineoxaliplatinlenvatinibiparomlimabtuvonralimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2600132618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132618.